JPMorgan analyst Rohin Patel initiated coverage of Haemonetics (HAE) with an Overweight rating and $116 price target Haemonetics has “multiple ...

Analyst Michael Petusky from Barrington maintained a Buy rating on Haemonetics (HAE – Research Report) and keeping the price target at $108.00. Don't Miss our Black Friday Offers: Michael Petusky’s ...

BOSTON, Dec. 3, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today ...